Retatrutide

LY3437943, LY-3437943

A synthetic peptide acting as a triple agonist for GLP-1, GIP, and glucagon receptors, designed for treating obesity and type 2 diabetes by promoting weight loss and glycemic control.

Molecular Profile

Formula C₂₂₁H₃₄₂N₄₆O₆₈

Mol. Weight 4731.33 g/mol

Sequence Gly-Glu-Pro-Pro...

Clinical Data Trials

Scientific Data Studies

Route	Dosage	Bioavailability
Subcutaneous (SC) 0.5-12 mg once weekly	0.5-12 mg once weekly	High (90%)	SUB

How It Works

How It Works: Retatrutide functions as a triple agonist, simultaneously activating GLP-1, GIP, and glucagon receptors to synergistically regulate glucose metabolism, appetite, and energy expenditure.

GLP-1 Receptor Activation: Enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes satiety to reduce caloric intake.
GIP Receptor Activation: Improves insulin sensitivity, facilitates lipid metabolism, and reduces fat deposition.
Glucagon Receptor Activation: Increases energy expenditure, promotes thermogenesis, and modulates hepatic glucose production without causing hyperglycemia.

Pairs Well With

Latest Clinical Trials

See All Clinical Trials

Completed PHASE1 NCT05548231

A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

Eli Lilly and Company

INTERVENTIONAL

Updated Dec 15, 2025

Completed PHASE1 NCT05757531

A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

Eli Lilly and Company

INTERVENTIONAL

Updated Dec 15, 2025

Recruiting PHASE3 NCT07165028

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Eli Lilly and Company

INTERVENTIONAL

Updated Dec 15, 2025

View All Clinical Trials

Latest Studies

See All Studies

Utility 3

pubmed Nov 26, 2025

Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders.

Cho. Yun Kyung YK; Jung. Chang Hee CH

Retatrutide is a new triple‑hormone peptide that hits GLP‑1, GIP and glucagon at once. Early studies show it can cause big drops in weight and blood sugar, plus possible liver and heart benefits, acting like the hormone mix after bariatric surgery. It’s still in clinical trials, so it isn’t something you can use yet, but it points to the next generation of powerful weight‑loss drugs.

Utility 3

pubmed Nov 24, 2025

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.

Abdelrahman. Riad Mohammed RM; Musa. Taha Hussein TH; Arbab. Ismail Adam IA; Sul...

GLP‑1 receptor agonists like liraglutide, semaglutide and tirzepatide are already proven to help people lose weight and control blood sugar. New drugs such as retatrutide are in late‑stage trials and could work even better or be useful for other health problems like fatty liver, kidney disease and heart failure. The field is also moving toward longer‑acting shots, combo pills and digital tools that make dosing easier, while cheaper generic versions are starting to appear.

Utility 2

pubmed Nov 7, 2025

Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.

Kanu. Chisom C; Clucas. Claudine C; Skalicky. Anne A; Samuelson. Ashley A; Goetz...

Researchers created a new 21‑question survey (EBAQ) to better capture how people with obesity feel hungry and what they eat, especially when they’re on a drug like retatrutide. The survey was tested with patients and doctors and was found clear and useful.

Browse All Studies